Management Team

Judith Kelleher-Andersson, Ph.D.
Founder, President and Chief Executive Officer (CEO)

Dr. Kelleher-Andersson has over twenty years of experience discovering and developing small-molecule, central nervous system therapeutics in the biotechnology industry. Prior to founding Neuronascent, Inc, she was Director of Drug Development and Research at Neuralstem, Inc., Centaur Pharmaceuticals and Cortex Pharmaceuticals, Inc. She strategically directed research and personnel toward indications with large unmet need. She headed the Alzheimer’s disease program in collaboration with Astra-Zeneca while at Centaur, and successfully brought a small-molecule agent to pre-nomination status (primary inventor). She invented a neurogenic depression therapeutic, while at Neuralstem, that is presently in Phase Ib. Dr. Kelleher-Andersson has over 70 US, European and World patents. She received her Ph.D. in biochemistry from University of Missouri-Columbia and completed post-graduate work at UCLA and University of California, San Francisco.

 

 

 


  » Home
» News & Events
» Contact Us
ABOUT US
Management Team
Directors & Advisors
Collaborators
Memberships
TECHNOLOGY
Neurogenesis
Drug Discovery
Intellectual Property
R&D PROGRAMS
Alzheimer's Disease (AD)
Depression
Parkinson's Disease (PD)
Down Syndrome
Ischemia
Hibernation and Ischemia
  © 2016 NeuroNascent, Inc. - All Rights Reserved - Website by TeraMark
This website contains forward-looking statements, which are made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are commonly identified by words such as “would,” “may,” “will,” “expects,” and other terms with similar meaning. Forward-looking statements are based on current beliefs, assumptions and expectations and speak only as of the date of this site and involve risks and uncertainties that could cause actual results to differ materially from current expectations.